Source BioScience Acquires CCL
In April 2025, Source BioScience UK Ltd, a leading provider of genomic services and histopathology diagnostics, acquired Cambridge Clinical Laboratories (CCL).
The acquisition complements Source BioScience’s established capabilities in genomics and multi-omics, and expands its existing clinical offering, which includes molecular diagnostics, digital pathology and clinical trial support, to provide a complete laboratory service portfolio. By offering comprehensive, end-to-end testing solutions, researchers can confidently progress candidates through R&D, to preclinical and clinical stages with one specialist outsourcing partner – minimising resource requirements and data bias across the entire development process, with the option for additional support in clinical research and diagnostics.
Our Laboratory
Following the acquisition, the CCL laboratory relocated to a new facility in June 2025. As part of this transition, we are currently undergoing UKAS assessment for the extension to scope for the new location.
While this assessment process is ongoing, assays covered by our accreditation scope performed at the new site are temporarily not covered under UKAS accreditation. As a result, the UKAS accreditation symbol will not appear on reports for these tests during this period.
Please note that:
The test methods, equipment, and quality management system remain unchanged.
All testing continues to be performed by the same trained staff using validated methods.
Internal quality controls, external quality assessment participation, and all laboratory quality processes remain in place in accordance with ISO 15189 requirements.
This temporary change reflects an administrative requirement related to the relocation of the laboratory, rather than any change to the scientific validity or reliability of the assays.
Once accreditation has been formally transferred the UKAS symbol will be reinstated on our reports.
Our Expertise
PERSONALISED HEALTHCARE
CCL is proud to provide healthcare professionals with UKAS accredited testing based in the heart of scientific development, Cambridge, UK.
Our experience is coupled with a rapidly growing portfolio of molecular and virology diagnostics, next generation sequencing, pharmacogenetic and patient profiling tests, all of which employ cutting-edge technology.
Quality service
Being a private and independent laboratory enables us to offer true value to our partners. We can respond to the ever-changing needs of the healthcare diagnostic market in a rapid and effective manner. This directly benefits the clinicians and healthcare providers we work with as they diagnose, treat and monitor their patients.
Our Promise
